Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
A Longitudinal Multi-Center Molecular Biomarker Discovery Registry for Patients With Hematologic Malignancies
NCT07154823 · View on ClinicalTrials.gov ↗
Study Summary
The TEMPUS AQUARIUS Study is a non-interventional, longitudinal observational study focused on hematological malignancies. It will collect rich molecular (multi-omic) and clinical data from patient cohorts through serial blood draws and the acquisition of leftover tissue and/or bone marrow aspirates during their routine therapy and disease monitoring. The primary goal is to understand the association between biomarkers and real-world clinical outcomes in these patient populations.
Conditions Studied
Interventions
- OTHER None - Observational Study
Study Locations (5)
Maryland
- The Center for Cancer and Blood Disorders — Bethesda
Nevada
- Cancer Care Specialists of Reno — Reno
Ohio
- Taylor Cancer Research Center — Maumee
Pennsylvania
- Cancer Care Associates of York — York
South Dakota
- Avera Cancer Institue — Sioux Falls
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 550 participants |
| Start Date | 2026-01-27 |
| Est. Completion | 2035-11 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07154823
The ClinicalTrials.gov registry entry for NCT07154823 describes a study currently listed as recruiting. It is categorized as an unspecified phase, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 550 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Tempus AI, which has 12 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 2 conditions, with Acute Myeloid Leukaemia (AML) appearing as the primary indexed condition, and to 1 intervention — of which None - Observational Study is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT07154823 reports 5 study locations spanning 5 distinct geographic areas — top geographies include Maryland, Nevada, Ohio. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT07154823 about?
NCT07154823 is a clinical study titled "A Longitudinal Multi-Center Molecular Biomarker Discovery Registry for Patients With Hematologic Malignancies". The TEMPUS AQUARIUS Study is a non-interventional, longitudinal observational study focused on hematological malignancies. It will collect rich molecular (multi-omic) and clinical data from patient cohorts through serial blood draws and the acquisition of leftover tissue and/or bone marrow aspirates...
What is the current status of trial NCT07154823?
This trial is currently recruiting. The enrollment target is 550 participants. The study started on 2026-01-27. Estimated completion is 2035-11.
What conditions does trial NCT07154823 study?
This clinical trial studies the following conditions: Acute Myeloid Leukaemia (AML), Follicular Lymphoma ( FL). These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT07154823?
The interventions under investigation include: None - Observational Study (OTHER). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT07154823?
This trial is sponsored by Tempus AI, which has 12 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT07154823 being conducted?
This trial has 5 study locations across Maryland, Nevada, Ohio, Pennsylvania, South Dakota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.